A New Year and a new look. For 2019 we have merged the Scrip 100 with In Vivo’s annual preview magazine, creating a new beast known as Outlook. This encompasses all the best aspects of both issues and covers more topic areas than ever before.
Outlook 2019 includes annual league tables for both the top 100 biopharmaceutical and top 100 medical technology companies, ranking the leaders of each sector by their 2017 full-year financial performance. A full analysis of the biopharmaceutical and medtech sectors’ financial data can be found on the Outlook 2019 hot topic page.
Monetary scrutiny is not the only reason to investigate the content of Outlook 2019. Bringing in something new, the Outlook...
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.
Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.
Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
